SCHEMBL7617877

SCHEMBL7617877

O=c1ccoc2ccc(O)cc12

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FTO Q9C0B1 3/20 0.72
MAOA P21397 8/20 0.53
MAOB P27338 8/20 0.53
ACHE P22303 1/20 0.51
MAPT P10636 3/20 0.50
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
TP53 P04637 2/20 0.50
CYP3A4 P08684 2/20 0.50
HPGD P15428 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
LMNA P02545 1/20 0.50
THRB P10828 1/20 0.50
ALOX15 P16050 1/20 0.50
CASP3 P42574 1/20 0.50
SENP8 Q96LD8 1/20 0.50
SENP7 Q9BQF6 1/20 0.50
SENP6 Q9GZR1 1/20 0.50
IP6K2 Q9UHH9 1/20 0.50
DYRK1A Q13627 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29799642 0.84 FTO (1.00) FTOMAOAMAOBMAPTNPC1
SCHEMBL546240 0.84 FTO (1.00) FTOMAOAMAOBMAPTNPC1
Methylene Chloride SCHEMBL27891472 0.79 FTO (0.89) FTOMAOAMAOBCYP3A4HPGD
SCHEMBL365385 0.78 MAOA (0.58) FTOMAOAMAOBACHEHPGD
SCHEMBL3681299 0.76 FTO (0.61) FTOMAOAMAOBACHEMAPT
SCHEMBL1094182 0.76 MAOA (0.59) FTOMAOAMAOBACHEDYRK1A
SCHEMBL21303291 0.76 MAOA (0.53) FTOMAOAMAOBACHEDYRK1A
SCHEMBL932337 0.76 MAOA (0.59) FTOMAOAMAOBACHEMAPT
SCHEMBL321544 0.76 MAOA (0.59) FTOMAOAMAOBACHEDYRK1A
SCHEMBL13665731 0.76 MAOA (0.53) FTOMAOAMAOBACHEDYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4192454-B1 AZABICYCLO-AMINO-TRIAZINE COMPOUNDS FOR MODULATING SPLICING FOR THE TREATMENT OF NEUROLOGICAL DISEASES SKYHAWK THERAPEUTICS INC (US) 2026-04-22 EP disclosed
US-20250353855-A1 HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS INC (US) 2025-11-20 US disclosed
US-20230020922-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-01-19 US disclosed
US-20210030022-A1 NOVEL USE OF SUBSTITUTED CHROMAN-6-OLS DSM IP ASSETS B.V. (NL) 2021-02-04 US disclosed
WO-2016097345-A1 LABELLED CHROMONE DERIVATIVES GE HEALTHCARE LIMITED (GB) 2016-06-23 WO disclosed
CN-102993147-B 4-chromone and 4-chromanone compound and purposes SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2015-09-09 CN disclosed
CN-101486701-B Chromanone compound and analogue and medical application thereof UNIV SHENYANG PHARMACEUTICAL 2013-06-19 CN disclosed
CN-102993147-A 4-chromone and 4-chromanone compounds and application thereof UNIV SHENYANG PHARMACEUTICAL 2013-03-27 CN disclosed
CN-102977064-A 4-chromone and 4-chromanone compounds and medical application thereof UNIV SHENYANG PHARMACEUTICAL 2013-03-20 CN disclosed
CN-101486715-B Novel oxazine compound and use for preventing platelet aggregation UNIV SHENYANG PHARMACEUTICAL 2013-01-23 CN disclosed
US-5919950-A SYNTHESIS OF SQUARATE DYES POLAROID CORPORATION (US) 1999-07-06 US disclosed
US-5627014-A COMPOSITIONS FOR ABSORBERS OF HEAT WHILE COLORING POLAROID CORPORATION (US) 1997-05-06 US disclosed
US-5607928-A Carbapenem derivatives containing a bicyclic ketone substituent and their use as anti-infectives ZENECA LIMITED (GB) 1997-03-04 US disclosed
EP-0695753-A1 Carbapenem derivatives containing a bicyclic substituent, process for their preparation, and their use ZENECA LIMITED (GB) 1996-02-07 EP disclosed
EP-0190015-B1 NOVEL 4H-1-BENZOPYRAN-4-ONES AND THEIR SULPHUR CONTAINING ANALOGS WARNER-LAMBERT COMPANY (US) 1989-01-25 EP disclosed
US-4780478-A Aminopropoxy-chromones useful as antidepressants MERCK PATENT GESELLSCHAFT MIT BERSCHRANKTER HAFTUNG (DE) 1988-10-25 US disclosed
US-4678787-A PSYCHOSIS, SCHIZOPHRENIA WARNER-LAMBERT COMPANY (US) 1987-07-07 US disclosed
EP-0190015-A1 Novel 4H-1-benzopyran-4-ones and their sulphur containing analogs WARNER-LAMBERT COMPANY (US) 1986-08-06 EP disclosed
US-4508732-A Basic ethers useful as antidepressant agents MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1985-04-02 US disclosed
US-4376123-A Hexahydroazepinyloxy-chromones useful as antidepressants MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1983-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210030022-A1 NOVEL USE OF SUBSTITUTED CHROMAN-6-OLS KMO, FFAR3, ACOX3 FTO 14/4885MAOA 344/4885MAOB 715/4885
US-20230020922-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SNRPA1 FTO 2943/4885MAOA 4459/4885MAOB 3954/4885
US-20250353855-A1 HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE HTT, HYPK, FH FTO 4160/4885MAOA 122/4885MAOB 59/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.